The main functions of Platinib (Pujihua) and which patients it is suitable for

Pralsetinib is a new type of targeted anti-cancer drug that is a highly selective RET kinase inhibitor. Its main mechanism of action is to inhibit the proliferation and survival of cancer cells by blocking the tumor cell signaling pathway driven by RET gene fusion or mutation. Abnormal activation of the RET gene has been found in a variety of tumors, especially in non-small cell lung cancer (NSCLC) and thyroid cancer. Platinib has become an important treatment option for RET fusion-positive tumors in recent years due to its high selectivity and good oral bioavailability.

In terms of clinical application, platinib is widely used to treat patients with locally advanced or metastatic non-small cell lung cancer carrying RET gene fusion. Compared with traditional chemotherapy, platinib shows more outstanding advantages in objective response rate and progression-free survival. At the same time, platinib also shows good efficacy for patients who have previously received platinum-based chemotherapy, making it one of the key therapeutic drugs for such patients. Its lower incidence of side effects also brings better tolerance and quality of life to patients.

In addition to lung cancer, platinib is also suitable for patients with RET fusion-positive medullary thyroid cancer (MTC) and other RET mutation-driven thyroid cancers. Studies have shown that in such patients, platinib can significantly reduce tumor size, delay disease progression, and reduce the need for radiation therapy or surgery to a certain extent. Platinib offers a new treatment option for thyroid cancer patients who are ineffective or intolerant to traditional therapies.

In general, Platinib is suitable for cancer patients with clear RET gene fusions or mutations, especially patients with non-small cell lung cancer and thyroid cancer. Due to its precise molecular target mechanism of action, platinib can achieve personalized treatment, improve efficacy and reduce ineffective medication. However, before use, genetic testing must be performed to confirm the RET fusion or mutation status to ensure that patients can benefit from the drug.

Reference link:https://www.drugs.com